Selecting COVID‐19 convalescent plasma for neutralizing antibody potency using a high‐capacity SARS‐CoV‐2 antibody assay

BACKGROUND: Efficacy of COVID‐19 convalescent plasma (CCP) is hypothesized to be associated with the concentration of neutralizing antibodies (nAb) to SARS‐CoV‐2. High capacity serologic assays detecting binding antibodies (bAb) have been developed; nAb assays are not adaptable to high‐throughput te...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transfusion
Main Authors: Goodhue Meyer, Erin, Simmons, Graham, Grebe, Eduard, Gannett, Michael, Franz, Sergej, Darst, Orsolya, Di Germanio, Clara, Stone, Mars, Contestable, Paul, Prichard, Alicia, Reik, Rita, Vassallo, Ralph, Young, Pampee, Busch, Michael P., Williamson, Phillip, Dumont, Larry J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Donor Infectious Disease Testing
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013397/
https://ncbi.nlm.nih.gov/pubmed/33554362
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/trf.16321
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados